brilanestrant inn developmental code names nonsteroidal combined selective estrogen receptor modulator serm selective estrogen receptor degrader serd discovered aragon pharmaceuticals development genentech treatment locally advanced metastatic estrogen receptor erpositive breast development brilanestrant discontinued roche april reached phase ii clinical trials treatment breast cancer prior discontinuation similarly tamoxifen serm brilanestrant shows capacity activate er certain contexts possesses weak estrogenic activity rat uterus unlike fulvestrant currently serd marketed brilanestrant steroid orally bioavailable need administered intramuscular brilanestrant found active tamoxifen fulvestrantresistant vitro models human breast side effects observed clinical studies brilanestrant thus far included diarrhea nausea fatigue mostly mildtomoderate brilanestrant structural analogue etacstil earlier combined serm serd abandoned commercial httpsenwikipediaorgwikibrilanestrant